Quarterly report pursuant to Section 13 or 15(d)

COMMITMENTS AND CONTINGENCIES (Details Narrative)

v3.22.2.2
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Loss Contingencies [Line Items]        
Termination agreement description     The employment agreements as amended for the Company’s Executive Chairman and CEO each contain termination provisions whereby if they are terminated without cause or following a material change, as defined therein, they will receive salary through the date of termination plus an additional 24 months, bonus that would be earned during the full year when the termination became effective (or a lump sum of 50% of the full target bonus), all stock options shall vest and healthcare benefits will continue for 24 months. The Company’s General Counsel’s employment agreement, as amended, contains an 18-month severance payment in the instance of a termination without cause or following a material change, as defined therein.  
Issuance of stock for services, shares 235,556 180,634 269,775 387,151
Professional fees $ 108,841 $ 473,017 $ 966,251 $ 1,427,703
Research and development expense 245,853 $ 164,378 $ 704,902 385,785
Chairman and CEO [Member]        
Loss Contingencies [Line Items]        
Description of nature and effects     The employment agreements, as amended, for the Company’s Executive Chairman and CEO each contain a transaction bonus in the instance any of the Company’s assets are sold or sublicensed or if the Company or its subsidiaries is acquired, equal to 1.75% of the consideration received by the Company. The employment agreement, as amended, for the Company’s General Counsel contains a similar transaction bonus equal to 0.5% of consideration received by the Company  
Employment Agreements [Member]        
Loss Contingencies [Line Items]        
Accrued salaries $ 758,751   $ 758,751  
License Agreement [Member] | IGL Pharma Inc [Member]        
Loss Contingencies [Line Items]        
Agreement term     20 years  
Issuance of stock for services, shares     12,500  
Royalty percentage     4.50%  
Sublicense percentage     5.00%  
Professional fees     $ 8,500  
License Agreement [Member] | IGL Pharma Inc [Member] | Upon Commercialization [Member]        
Loss Contingencies [Line Items]        
Other expenses     2,000,000  
License Agreement [Member] | IGL Pharma Inc [Member] | Maximum [Member]        
Loss Contingencies [Line Items]        
Other expenses     410,000  
Consulting Agreement [Member]        
Loss Contingencies [Line Items]        
Research and development expense     704,902 $ 385,785
Consulting Agreement [Member] | IGL Pharma Inc [Member]        
Loss Contingencies [Line Items]        
Other expenses     9,355  
Rent payments     $ 8,500